Mumps is a contagious viral disease caused by mumps virus, classically presenting with parotitis and sometimes leading to complications such as orchitis, meningitis, or hearing loss. Vaccination substantially reduces incidence.
The U.S. recorded 2,280 measles cases in 2025, the highest since 1991, with 982 cases already confirmed in early 2026. North London faces an outbreak with 34 children infected in Enfield, while Philadelphia issued an exposure alert for the international airport.
Measles cases are rising across multiple states, with over 40 cases at a Florida college and 18 cases in North Carolina since December. Federal health officials are urging vaccination as the U.S. recorded 2,280 cases in 2025.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07358910 |
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective |
RECRUITING | |
| NCT07338851 |
the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines |
NOT_YET_RECRUITING | |
| NCT06967181 |
A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06331702 |
Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR) |
COMPLETED | PHASE4 |
| NCT06208683 |
The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT05952505 |
Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines |
UNKNOWN | PHASE4 |
| NCT05894395 |
Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination |
RECRUITING | PHASE3 |
| NCT05279248 |
The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine |
UNKNOWN | PHASE4 |
| NCT05145166 |
Safety Study of Live Attenuated Mumps Vaccines in Junior High School Students Under 14 Years Old |
COMPLETED | |
| NCT05065177 |
Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants |
COMPLETED | PHASE3 |
